What is the appropriate second‑line systemic therapy for a patient with small‑cell lung cancer who has completed cisplatin‑etoposide and now has residual thoracic disease with new pulmonary nodules?

Second-Line Treatment After Cisplatin-Etoposide for Small Cell Lung Cancer

For this patient with residual thoracic disease and new pulmonary nodules after completing cisplatin-etoposide, the preferred second-line options are topotecan, lurbinectedin, or tarlatamab as single-agent therapy 1.

Treatment Selection Algorithm

The critical first step is determining the chemotherapy-free interval from completion of first-line therapy:

If Chemotherapy-Free Interval < 90 Days (Refractory Disease)

Single-agent chemotherapy is strongly preferred over combination therapy due to better risk-benefit balance 1, 2. The preferred agents are:

• Topotecan (FDA-approved, established standard)
• Lurbinectedin (33% response rate in phase II data, 22% RR in refractory patients) 2
• Tarlatamab (newest option with >9 month duration of response, substantially longer than other agents) 1

Key consideration: Tarlatamab requires 24-hour inpatient monitoring after the first two doses due to unique immune-mediated toxicities (cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome), though grade ≥3 events are rare (1% and 0% respectively at 10mg dose) 1.

If Chemotherapy-Free Interval ≥ 90 Days (Sensitive-Relapsed Disease)

You have two equally valid options 1, 2:

1. Rechallenge with platinum-based regimen (cisplatin-etoposide or carboplatin-etoposide)

   • Response rate: 49% vs 25% for topotecan 2
   • PFS: 4.7 vs 2.7 months 2
   • No OS difference in trials (7.5 vs 7.4 months), likely due to crossover 2
   • Higher myelosuppression but better tolerability than topotecan

2. Single-agent therapy (topotecan, lurbinectedin, or tarlatamab)

   • Lurbinectedin shows 45% RR in sensitive-relapsed patients 2
   • Better toxicity profile than combination therapy

Clinical Context for This Patient

Given the presentation of residual thoracic disease with new pulmonary nodules, this suggests either:

• Progressive disease during/immediately after treatment (refractory), OR
• Early relapse shortly after completion

If the chemotherapy-free interval is < 90 days: Choose single-agent topotecan, lurbinectedin, or tarlatamab. Cross-trial comparisons suggest lurbinectedin and tarlatamab are more effective than topotecan, with tarlatamab showing the longest duration of response 1.

If the chemotherapy-free interval is ≥ 90 days: Consider platinum rechallenge if the patient has good performance status and tolerates combination therapy, as this provides higher response rates and PFS 2.

Critical Pitfalls to Avoid

• Do not continue immunotherapy if the patient progressed on maintenance immunotherapy—there is no evidence supporting this approach 2
• Do not use second-line immunotherapy alone in immunotherapy-naïve patients outside clinical trials 2
• Avoid multi-agent chemotherapy in refractory disease (chemotherapy-free interval <90 days) due to unfavorable risk-benefit ratio 1, 2

Strength of Evidence

The 2025 ASCO guideline 1 provides the most current recommendations with moderate evidence quality and strong recommendation strength for both refractory and sensitive-relapsed settings. The addition of tarlatamab represents the newest FDA-approved option, though direct head-to-head comparisons with lurbinectedin are ongoing (DeLLphi-304 trial) 1.